VRTX

$432.76

▲+2.86%

wb_incandescent Backtest

Stock

Vertex Pharmaceuticals Incorporated Common Stock

Official Company Name: Vertex Pharmaceuticals Incorporated

Stock Symbol: VRTX

Stock Market: NASDAQ Global Select - NASDAQ

Currency: United States dollar - USD

business Vertex Pharmaceuticals Incorporated Company Profile

VRTX Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▲+48.84%

file_download

Daily closing prices, with moving averages and volumes - United States dollar (USD)
Moving averages:

  • EMA20
  • SMA50
  • SMA200

Company Description

Vertex Pharmaceuticals Incorporated is a pharmaceuticals and biotherapeutics company. It notably produces drugs and genetic therapies for cystic fibrosis and other skin conditions, such as pain, sickle cell disease, beta-thalassemia, hormonal deficiencies, kidney diseases, Duchenne muscular dystrophy, and diabetes.

business Vertex Pharmaceuticals Incorporated Company Profile

VRTX Stock Data

Open $423.20
High $433.67
Low $422.95
Close $432.76
Volume 1,102,200
Previous Close $420.74
1-Day Change 12.02
1-Year Change 142.00
Average Daily Volume 1,243,173
52-Week High $446.08
52-Week Low $285.18

VRTX Stock References

warning

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.